The standard cholesterol test has misled millions of patients. A “normal” total cholesterol can coexist with dramatically elevated cardiovascular risk; a seemingly elevated LDL can carry very little risk if the particle profile is favourable. Understanding your full lipid panel — including LDL subfractions, ApoB, non-HDL cholesterol, and the triglyceride-to-HDL ratio — is the difference between meaningful cardiovascular risk management and a superficial reassurance that your cholesterol is “fine.”

The Standard Lipid Panel: What It Measures and What It Misses

A basic lipid panel measures total cholesterol, HDL-C (high-density lipoprotein cholesterol), triglycerides, and LDL-C (low-density lipoprotein cholesterol, usually calculated via the Friedewald equation). These four values are the foundation of cardiovascular risk assessment in clinical practice worldwide.

The Friedewald equation (LDL-C = Total Cholesterol – HDL-C – Triglycerides/5) is reasonably accurate when triglycerides are below 4.0 mmol/L (354 mg/dL), but becomes significantly unreliable at higher triglyceride levels — which is precisely the situation in patients with metabolic syndrome and insulin resistance.^[1]

LDL: Particle Size Matters More Than Concentration

LDL particles exist in a spectrum of sizes and densities. Pattern A LDL consists of predominantly large, buoyant particles; Pattern B consists of small, dense LDL particles. These two patterns carry very different cardiovascular risk, yet they can produce identical LDL-C values.^[2]

Small dense LDL particles are more atherogenic for three reasons: they penetrate the arterial wall more readily, they have lower affinity for LDL receptors (prolonging their residence in circulation), and they are more susceptible to oxidative modification, which is the key step in foam cell formation and plaque development.^[3]

A patient with LDL-C of 3.5 mmol/L (135 mg/dL) and Pattern A (large fluffy) LDL has a much lower cardiovascular risk than a patient with LDL-C of 2.8 mmol/L (108 mg/dL) and Pattern B (small dense) LDL. The standard LDL-C test does not distinguish between these two.

ApoB: The Gold Standard for Atherogenic Particle Count

Apolipoprotein B (ApoB) is the structural protein present in every atherogenic lipoprotein particle: VLDL, IDL, LDL, and Lp(a). Crucially, there is exactly one ApoB molecule per particle. Therefore, measuring ApoB gives a direct count of the total number of atherogenic particles in circulation, regardless of how much cholesterol each particle contains.^[4]

Multiple prospective studies and meta-analyses have confirmed that ApoB is a stronger predictor of cardiovascular events than LDL-C.^[5] The ACC/AHA 2018 guidelines acknowledged ApoB as a “risk-enhancing factor” that should be considered when the decision to initiate or intensify lipid-lowering therapy is uncertain.^[6]

Target ApoB levels: below 0.9 g/L for primary prevention; below 0.7 g/L for high-risk patients (established ASCVD, diabetes with organ damage, familial hypercholesterolaemia).

Non-HDL Cholesterol: The Practical ApoB Surrogate

For clinics where ApoB testing is not available, non-HDL cholesterol (Total Cholesterol minus HDL-C) is the best practical surrogate. It captures the cholesterol content of all atherogenic particles — VLDL, IDL, LDL, and Lp(a).^[7] Target non-HDL-C: below 3.4 mmol/L (131 mg/dL) for general population; below 2.6 mmol/L (100 mg/dL) for high-risk patients.

The Triglyceride-to-HDL Ratio: A Free Insulin Resistance Screen

The ratio of triglycerides to HDL cholesterol (Trig:HDL ratio) is a powerful clinical tool that is widely underused. In South Asian and Middle Eastern populations (highly relevant to our patient population at SehaTalks), a Trig:HDL ratio above 1.5 (in mmol/L units) or above 3.5 (in mg/dL units) is a strong indicator of small dense LDL predominance and significant insulin resistance.^[8]

The landmark Physicians Health Study demonstrated that a Trig:HDL ratio above 4.0 (mg/dL) was associated with a 16-fold increased risk of myocardial infarction compared to a ratio below 1.0, even after adjusting for other cardiovascular risk factors.^[9]

In our clinical practice, a Trig:HDL ratio above 1.5 in a fasted sample triggers immediate investigation for insulin resistance (fasting insulin and HOMA-IR calculation), independent of the LDL-C value.

Lipoprotein(a): The Underdiagnosed Hereditary Risk Factor

Lp(a) (lipoprotein-little-a) is a modified LDL particle with an additional apolipoprotein(a) attached. Its plasma concentration is 80–90% genetically determined and largely unresponsive to lifestyle or standard lipid-lowering therapy.^[10] Elevated Lp(a) (above 50 mg/dL or 125 nmol/L) is present in approximately 20% of the population and is an independent risk factor for ASCVD, aortic valve stenosis, and stroke.

Every patient should have Lp(a) measured once in their lifetime, ideally before age 40. Current treatments targeting Lp(a) specifically (RNA interference agents — pelacarsen, olpasiran) are in late-stage clinical trials and showing dramatic reductions in Lp(a) levels.^[11]

Dr. Ahmed’s Cardiometabolic Risk Assessment Protocol

At SehaTalks, we assess cardiovascular risk using the full panel: LDL-C, non-HDL-C, ApoB (where available), Trig:HDL ratio, Lp(a), fasting insulin (HOMA-IR), hsCRP (inflammatory marker), and 10-year ASCVD risk score. We do not reassure patients on the basis of LDL-C alone. The goal is to understand the complete atherogenic burden and address it through a combination of lifestyle optimisation and, where necessary, pharmacotherapy.

Chronic kidney disease (CKD) and Type 2 diabetes are so frequently intertwined that the medical community has coined a specific term for their convergence — diabetic kidney disease (DKD). It affects approximately 40% of people with Type 2 diabetes and is the leading cause of end-stage renal disease (ESRD) requiring dialysis in most developed countries.^[1] Yet most patients with early DKD have no symptoms whatsoever. The kidneys can lose 50–60% of their function before any clinical warning sign appears.

How Hyperglycaemia Damages the Kidneys

The glomerulus — the kidney’s filtering unit — is a delicate structure of specialised cells including podocytes, endothelial cells, and mesangial cells. Chronic hyperglycaemia damages each of these cell types through multiple converging mechanisms:^[2]

• Advanced glycation end-products (AGEs): Glucose reacts with proteins throughout the body to form AGEs, which activate specific receptors (RAGE) on glomerular cells, triggering oxidative stress and pro-inflammatory gene expression.
• Haemodynamic injury: Hyperglycaemia causes preferential dilation of the afferent arteriole while the efferent arteriole remains constricted, increasing intraglomerular pressure. This mechanical stress directly damages the filtration barrier and drives proteinuria.
• Podocyte injury and loss: Podocytes are the gatekeepers of glomerular filtration. They are terminally differentiated and cannot regenerate. Diabetes-induced oxidative stress and mechanical stress cause podocyte apoptosis; as podocytes are lost, proteinuria increases and glomerulosclerosis progresses.
• Tubulointerstitial fibrosis: Activation of TGF-β1 promotes mesangial expansion and tubulointerstitial fibrosis — the structural change that permanently reduces GFR.

The Critical Role of Albuminuria: The UACR Test

The earliest detectable sign of diabetic kidney disease is microalbuminuria — the leakage of small amounts of albumin into the urine. This is detected by the urine albumin-to-creatinine ratio (UACR), a simple morning urine test.^[3]

• Normal: UACR below 3 mg/mmol (below 30 mg/g)
• Microalbuminuria (A2): 3–30 mg/mmol (30–300 mg/g) — early DKD, high reversibility with intervention
• Macroalbuminuria (A3): Above 30 mg/mmol (above 300 mg/g) — established DKD, progressive without treatment

Current guidelines recommend annual UACR testing for all patients with Type 2 diabetes, beginning at diagnosis (unlike Type 1, where screening begins 5 years post-diagnosis).^[4] The window of opportunity for intervention is widest at the microalbuminuria stage — regression to normal is achievable in up to 30% of patients with optimal metabolic control.

eGFR: Staging Kidney Disease

Estimated glomerular filtration rate (eGFR) quantifies how well the kidneys are filtering. CKD staging by eGFR (the CGA classification of KDIGO 2022):^[5]

• G1: eGFR ≥90 (normal or high) – diagnosis requires albuminuria or structural abnormality
• G2: eGFR 60–89 (mildly decreased)
• G3a: eGFR 45–59 (mild-moderately decreased)
• G3b: eGFR 30–44 (moderate-severely decreased)
• G4: eGFR 15–29 (severely decreased) – nephrology referral essential
• G5: eGFR below 15 – kidney failure, dialysis or transplant planning

The Therapeutic Revolution: SGLT2 Inhibitors and Finerenone

The past decade has produced the most significant advances in DKD treatment in 30 years, centred on two drug classes:

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce intraglomerular pressure by increasing natriuresis and reducing afferent arteriole tone — a mechanism entirely distinct from their glucose-lowering effect. The EMPA-KIDNEY trial (empagliflozin) showed a 28% relative risk reduction in CKD progression or cardiovascular death in patients with CKD regardless of diabetes status.^[6] The DAPA-CKD trial (dapagliflozin) demonstrated a 39% reduction in the composite of eGFR decline ≥50%, ESRD, renal or cardiovascular death.^[7]

Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has demonstrated additive kidney protection on top of ACE inhibitor/ARB therapy in the FIDELIO-DKD and FIGARO-DKD trials, reducing proteinuria and slowing eGFR decline.^[8] It is now recommended in major guidelines as add-on therapy for DKD at UACR above 30 mg/mmol.

Blood Pressure and RAS Blockade: The Cornerstone

Renin-angiotensin system (RAS) blockade with ACE inhibitors (ramipril, enalapril) or ARBs (losartan, irbesartan) remains the cornerstone of DKD treatment. They reduce intraglomerular pressure by dilating the efferent arteriole, reduce proteinuria by 35–40%, and slow eGFR decline independently of blood pressure effects.^[9] Target blood pressure in DKD is below 130/80 mmHg, and below 120/80 in those with significant proteinuria.

Dietary Management in CKD and Diabetes

Nutrition management in DKD requires balancing multiple competing concerns:^[10]

• Protein: Moderate protein restriction (0.8g/kg/day) slows GFR decline in advanced CKD (G4–G5). In earlier stages, restriction is not necessary but excessive protein (>1.5g/kg/day) should be avoided.
• Potassium: Hyperkalaemia risk rises with declining eGFR; potassium-rich foods (bananas, potatoes, tomatoes, legumes) require monitoring when eGFR falls below 30.
• Phosphate: Phosphate retention contributes to renal osteodystrophy and cardiovascular calcification; processed foods with phosphate additives should be minimised.
• Sodium: Restricting sodium to below 2,000 mg/day reduces blood pressure and proteinuria.

A persistent myth in medicine holds that telemedicine is a second-best substitute for in-person care — acceptable in a pandemic, but not a genuine clinical setting. Multiple systematic reviews, randomised trials, and large population studies published over the past decade have comprehensively dismantled this view. For chronic disease management — including Type 2 diabetes, hypertension, CKD, and cardiovascular disease — telemedicine achieves outcomes equivalent to or superior to standard in-person care, with higher patient satisfaction, lower cost, and greater access equity. This article reviews the evidence and explains how our telemedicine model at SehaTalks is structured to deliver genuine clinical excellence.

The Evidence Base: Diabetes Management via Telemedicine

A 2023 Cochrane systematic review of 22 randomised controlled trials involving 7,408 participants with Type 2 diabetes found that telemedicine-delivered diabetes management produced HbA1c reductions equivalent to standard in-person care, with the pooled effect favouring telemedicine by a small margin (standardised mean difference of −0.21, 95% CI −0.30 to −0.12) when structured digital support was included.^[1]

The REACH trial — a multisite US RCT of video-based diabetes care vs. in-person care — demonstrated equivalent HbA1c reductions at 12 months (telemedicine: −1.4%, in-person: −1.2%), with telemedicine participants reporting significantly higher satisfaction with care access and appointment adherence.^[2]

The most striking finding from the COVID-19 pandemic-forced transition to telemedicine was that for many chronic disease patients, clinical outcomes did not worsen and in some metrics improved. A large UK primary care study (n = 145,000) found that patients with Type 2 diabetes who transitioned to telephone and video consultations maintained equivalent HbA1c trajectories compared to the 12 months prior, despite the pandemic context.^[3]

Why Telemedicine Often Outperforms In-Person Care for Chronic Disease

Several well-documented mechanisms explain why telemedicine can match or exceed in-person care for chronic disease management:

Frequency of Contact

In traditional in-person care, the standard of practice for stable T2D is quarterly or 6-monthly appointments. The logistical friction of travel, parking, waiting rooms, and time off work means patients often miss appointments or arrive unprepared. Telemedicine removes these barriers, making more frequent, shorter touchpoints feasible and preferred by patients.

A meta-analysis of 17 studies found that every additional telemedicine touchpoint per month was associated with a 0.15% additional HbA1c reduction, suggesting that contact frequency — not contact mode — is the primary driver of chronic disease outcomes.^[4]

Real-Time Data Integration

Modern telemedicine enables integration of continuous glucose monitor (CGM) data, home blood pressure readings, and wearable activity data directly into the consultation interface. A clinician reviewing 14 days of CGM data before a video consultation has far richer clinical information than one reviewing a fasting glucose taken the morning of an in-person appointment. Time in Range (TIR) data from CGM has been shown to correlate more strongly with HbA1c and complication risk than isolated glucose measurements.^[5]

Medication Adherence

Medication non-adherence is one of the largest modifiable contributors to poor chronic disease outcomes — estimated to account for 50% of treatment failures in hypertension and diabetes.^[6] Telemedicine programmes that include structured messaging support and pharmacist-led reviews have shown 15–25% improvements in medication adherence compared to standard in-person care, primarily because the lower barrier to contact means patients are more likely to raise concerns about side effects, cost, or dosing before abandoning medication.^[7]

The Global Access Advantage

For the significant proportion of patients with metabolic disease in low-access settings — rural populations, patients in countries with limited specialist availability, expatriates requiring English-language care while abroad, or patients with mobility limitations — telemedicine is not merely equivalent to in-person care; it is the only access to specialist care available.

The World Health Organization’s 2023 global digital health strategy identifies telemedicine-delivered chronic disease management as a priority intervention for closing the access gap in non-communicable disease care, particularly for high-burden conditions (diabetes, hypertension, CKD) in low- and middle-income countries.^[8]

What Cannot Be Done by Telemedicine: Honest Limitations

Clinical honesty requires acknowledging what telemedicine cannot replace. Physical examination — cardiac auscultation, abdominal palpation, retinal examination for diabetic retinopathy, peripheral neuropathy assessment with monofilament, foot inspection — requires in-person contact. Patients with complex multi-system disease requiring physical assessment should have annual in-person evaluations supplemented by telemedicine for ongoing management.^[9]

Laboratory testing also requires in-person phlebotomy. At SehaTalks, we provide patients with standardised laboratory test requisitions that can be fulfilled at local diagnostic laboratories globally, with results shared electronically before telemedicine consultations.

The SehaTalks Telemedicine Model: How It Works

Our structured telemedicine protocol is designed to replicate — and in many respects exceed — the clinical standard of in-person metabolic care:

• Initial consultation (45–60 minutes): Comprehensive metabolic history, cardiovascular risk assessment, review of complete blood panel (emailed in advance), 10-year ASCVD risk score calculation, and personalised programme design.
• Follow-up consultations (20–25 minutes, every 8 weeks): HbA1c trend review, CGM/glucose data analysis, body weight and waist circumference tracking, medication adjustment, and lifestyle coaching.
• Between-appointment support: WhatsApp access for urgent clinical questions. Queries are reviewed within 24 hours on business days.
• Medication management: Prescriptions and referral letters provided electronically; coordination with local pharmacies and specialists as required.